Business Context and Reporting Period
This Form 8-K is a current report filed by Inmune Bio, Inc. on August 23, 2021. The company is incorporated in Nevada and trades on the NASDAQ Stock Market under the symbol INMB. The registrant is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes or operational updates were reported in this filing. The document serves solely to disclose a specific corporate event.
Guidance, Outlook, and Management Commentary
Item 8.01 Other Events: The company disclosed that Mark Lowdell, the Chief Scientific Officer, was interviewed by TW Research Group LLC. The full text of this interview is filed as Exhibit 99.1. No forward-looking guidance, risk updates, or unusual items were detailed within the body of this report.
Investor Verification Checklist
- Review Exhibit 99.1 to access the full transcript of the interview with Chief Scientific Officer Mark Lowdell.
- Verify the company's status as an emerging growth company and its implications for financial reporting standards.
- Consult the company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains none.